ReACT Therapeutics developed 5th-gen potent and selective inhibitors to target Breast Cancer Resistance Protein, a key treatment failure cause. Our globally protected lead compound extends the duration of drug effects in existing and new cancer drugs. We could impact across >40 known cancer drugs and >14 cancer indications. Our lead compound combined with irinotecan, a gold standard chemotherapy, has not only doubled irinotecan’s efficacy but also increased mouse survival by a factor of 5.